H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Immunology D-index 89 Citations 26,477 214 World Ranking 444 National Ranking 265

Overview

What is he best known for?

The fields of study he is best known for:

  • Antibody
  • Gene
  • Immune system

His primary scientific interests are in Antibody, Immunology, Molecular biology, Monoclonal antibody and Receptor. The Antibody study combines topics in areas such as In vivo, Recombinant DNA, Antigen and Virology. His Immunology research is multidisciplinary, relying on both Cytotoxic T cell and Cancer research.

His Molecular biology research includes elements of Transgene, Tyrosine kinase, Syk, Complement system and Antibody-dependent cell-mediated cytotoxicity. His Monoclonal antibody research incorporates themes from Cancer biology and Cancer therapy. His Receptor research includes themes of Alpha, Immune complex, Phagocytosis and Arthus reaction.

His most cited work include:

  • Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange (701 citations)
  • Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange (701 citations)
  • Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. (656 citations)

What are the main themes of his work throughout his whole career to date?

Jan G. J. van de Winkel mainly focuses on Antibody, Immunology, Receptor, Molecular biology and Monoclonal antibody. His studies deal with areas such as Cancer research, Antigen and Virology as well as Antibody. His Cancer research study integrates concerns from other disciplines, such as Cancer and Epidermal growth factor receptor.

His Immunology study combines topics from a wide range of disciplines, such as In vivo and Microbiology. His Receptor research integrates issues from Signal transduction and Cell biology. His research in Molecular biology intersects with topics in Genetically modified mouse, Transgene, Recombinant DNA, Immunoglobulin G and Epitope.

He most often published in these fields:

  • Antibody (67.80%)
  • Immunology (68.47%)
  • Receptor (40.68%)

What were the highlights of his more recent work (between 2010-2017)?

  • Antibody (67.80%)
  • Molecular biology (35.93%)
  • Immunology (68.47%)

In recent papers he was focusing on the following fields of study:

Jan G. J. van de Winkel mainly investigates Antibody, Molecular biology, Immunology, Cancer research and Antibody-dependent cell-mediated cytotoxicity. His Antibody research is multidisciplinary, incorporating perspectives in Antigen and Virology. His work deals with themes such as Recombinant DNA, Immunoglobulin G, Immune system and Immunoglobulin E, Galactose α 1 3 galactose, which intersect with Molecular biology.

CD20, Immunotherapy, Fc receptor, Daratumumab and Immunoglobulin A are the core of his Immunology study. His Cancer research study incorporates themes from Cytotoxic T cell and Growth factor receptor. The concepts of his Antibody-dependent cell-mediated cytotoxicity study are interwoven with issues in Epidermal growth factor receptor and Effector.

Between 2010 and 2017, his most popular works were:

  • Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors (623 citations)
  • Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors (623 citations)
  • Complement is activated by IgG hexamers assembled at the cell surface. (384 citations)

In his most recent research, the most cited papers focused on:

  • Gene
  • Antibody
  • Immune system

The scientist’s investigation covers issues in Antibody, Immunology, Molecular biology, Immunotherapy and Cytotoxic T cell. Jan G. J. van de Winkel regularly ties together related areas like Dissociation constant in his Antibody studies. The various areas that Jan G. J. van de Winkel examines in his Immunology study include Signal transduction and Binding site.

His research investigates the connection with Molecular biology and areas like Immunoglobulin G which intersect with concerns in Innate immune system, Cell killing, Complement component 5a and Complement system. Jan G. J. van de Winkel has included themes like IgG binding, Receptor, Immune complex and Bispecific Antibody MDX-H210 in his Immunotherapy study. His Cytotoxic T cell study combines topics in areas such as Stromal cell, Complement-dependent cytotoxicity and SLAMF7, Isatuximab, Daratumumab.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications.

Jan G.J. van de Winkel;Peter J.A. Capel.
Immunology Today (1993)

999 Citations

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

Marijn van der Neut Kolfschoten;Janine Schuurman;Mario Losen;Wim K. Bleeker.
Science (2007)

802 Citations

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

Jessica L Teeling;Ruth R French;Mark S Cragg;Jeroen van den Brakel.
Blood (2004)

716 Citations

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

Michel De Weers;Yu Tzu Tai;Michael S. Van Der Veer;Joost M. Bakker.
Journal of Immunology (2011)

646 Citations

Impaired IgG-Dependent Anaphylaxis and Arthus Reaction in FcγRIII (CD16) Deficient Mice

Wouter L.W Hazenbos;J.Engelbert Gessner;Frans M.A Hofhuis;Henri Kuipers.
Immunity (1996)

464 Citations

Complement is activated by IgG hexamers assembled at the cell surface.

Christoph A. Diebolder;Frank J. Beurskens;Rob N. de Jong;Roman I. Koning.
Science (2014)

394 Citations

Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility.

Chieko Kyogoku;Hilde M. Dijstelbloem;Naoyuki Tsuchiya;Yoko Hatta.
Arthritis & Rheumatism (2002)

376 Citations

Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies

Yashwant M. Deo;Robert F. Graziano;Roland Repp;Jan G.J. van de Winkel.
Immunology Today (1997)

353 Citations

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo

Aran F Labrijn;Antonio Ortiz Buijsse;Ewald T J van den Bremer;Annemiek Y W Verwilligen.
Nature Biotechnology (2009)

349 Citations

Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1

Marjan Hezareh;Ann J. Hessell;Richard C. Jensen;Jan G. J. van de Winkel.
Journal of Virology (2001)

342 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Jan G. J. van de Winkel

Paul W. H. I. Parren

Paul W. H. I. Parren

Leiden University Medical Center

Publications: 125

Falk Nimmerjahn

Falk Nimmerjahn

University of Erlangen-Nuremberg

Publications: 62

Gestur Vidarsson

Gestur Vidarsson

University of Amsterdam

Publications: 48

Theo Rispens

Theo Rispens

University of Amsterdam

Publications: 47

Jeffrey V. Ravetch

Jeffrey V. Ravetch

Rockefeller University

Publications: 46

P. Mark Hogarth

P. Mark Hogarth

University of Melbourne

Publications: 44

J. Sjef Verbeek

J. Sjef Verbeek

Leiden University Medical Center

Publications: 43

Ronald P. Taylor

Ronald P. Taylor

University of Virginia

Publications: 42

Robert P. Kimberly

Robert P. Kimberly

University of Alabama at Birmingham

Publications: 38

Pierre Bruhns

Pierre Bruhns

Institut Pasteur

Publications: 35

Marc Daëron

Marc Daëron

Institut Pasteur

Publications: 34

Renato C. Monteiro

Renato C. Monteiro

Université Paris Cité

Publications: 33

John R. Desjarlais

John R. Desjarlais

Pennsylvania State University

Publications: 32

Jeffrey C. Edberg

Jeffrey C. Edberg

University of Alabama at Birmingham

Publications: 29

Inger Sandlie

Inger Sandlie

University of Oslo

Publications: 29

Martin J. Glennie

Martin J. Glennie

University of Southampton

Publications: 29

Something went wrong. Please try again later.